Erdafitinib Update – Metastatic Urothelial Cancer
Arlene O. Siefker-Radtke, MD, explores the evolving role of erdafitinib in treating FGFR3-altered urothelial carcinoma.
Read MoreSelect Page
Posted by Daniel P. Petrylak, MD | Mar 2025
Arlene O. Siefker-Radtke, MD, explores the evolving role of erdafitinib in treating FGFR3-altered urothelial carcinoma.
Read MorePosted by Christopher E. Wolter, MD | Mar 2025
Christopher E. Wolter, MD, debates robotic uterosacral ligament suspension versus robotic sacrocolpopexy for pelvic organ prolapse repair.
Read MorePosted by Christian O. Twiss, MD, FAC | Mar 2025
Christian O. Twiss, MD, FACS, argues for robotic sacrocolpopexy as the optimal procedure for repairing apical pelvic organ prolapse.
Read MorePosted by John Sylvester, MD, FABS | Mar 2025
John Sylvester, MD, FABS, delves into the historical evolution, techniques, and efficacy of brachytherapy in prostate cancer management.
Read MorePosted by Shilpa Gupta, MD | Mar 2025
Shilpa Gupta, MD, explores the evolving treatment paradigm in metastatic urothelial carcinoma following the EV-302 trial.
Read More